微小RNA-31通过HIF1α调控T细胞代谢并促进小鼠慢性移植物抗宿主病发病
该研究在小鼠异基因造血细胞移植模型中,通过寡核苷酸芯片发现移植后异基因T细胞中微小RNA-31(miR-31)显著升高,并利用遗传和药理学方法证实miR-31是驱动慢性移植物抗宿主病(cGVHD)T细胞致病性的关键分子。miR-31缺陷T细胞可改善皮肤和肺部cGVHD,减少T细胞扩增和Th17分化、增加Treg生成与功能;全身给予miR-31特异性抑制剂可减轻cGVHD,而miR-31缺陷CD8 T细胞仍保持糖代谢、细胞毒活性和移植物抗白血病效应。
要点
- 移植后异基因T细胞中miR-31显著升高,miR-31缺陷T细胞可改善皮肤和肺部cGVHD。
- miR-31缺陷减少T细胞扩增和Th17分化、增加Treg生成与功能,并上调HIF1抑制因子。
- 全身给予miR-31特异性抑制剂可减少供者T细胞扩增、改善Treg生成并减轻cGVHD。
核心结论
- miR-31是cGVHD中T细胞致病性的关键驱动因素,但不是抗白血病活性的关键驱动因素。
- miR-31是驱动cGVHD发病的关键分子,并代表控制cGVHD的一种新的潜在治疗靶点。
研究设计与样本
- 临床前小鼠研究,使用寡核苷酸芯片鉴定移植后异基因T细胞中升高的miR,并采用遗传和药理学方法验证miR-31在cGVHD中的作用。
- 研究对象为小鼠异基因造血细胞移植(HCT)后的供者T细胞及受体。
主要发现
- 使用寡核苷酸芯片发现miR-31在移植后小鼠异基因T细胞中显著升高。
- 接受miR-31缺陷T细胞的受体显示皮肤和肺部cGVHD改善。
- miR-31缺陷减少T细胞扩增和Th17细胞分化,但增加调节性T细胞(Treg)的生成和功能。
- miR-31促进同种抗原诱导Treg中神经纤毛蛋白-1(neuropilin-1)下调和Foxp3丢失及干扰素-γ产生。
- miR-31是同种异基因T细胞中缺氧诱导因子1α(HIF1α)上调所必需的;miR-31缺陷CD4 T细胞在缺氧下显示激活、存活、Th17分化和糖酵解代谢受损。
关键数值与推荐
- miR-31缺陷T细胞中HIF1抑制因子(factor-inhibiting HIF1,miR-31的直接靶点)上调,对减弱T细胞致病性至关重要。
- miR-31缺陷CD8 T细胞维持完整的糖代谢、细胞毒活性和移植物抗白血病反应。
- 全身给予miR-31特异性抑制剂有效减少供者T细胞扩增、改善Treg生成并减轻cGVHD。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic graft-versus-host disease (cGVHD) remains a major obstacle impeding successful allogeneic hematopoietic cell transplantation (HCT). MicroRNAs (miRs) play key roles in immune regulation during acute GVHD development. Preclinical studies to identify miRs that affect cGVHD pathogenesis are required to develop these as potential lifesaving interventions. Using oligonucleotide array, we identified miR-31, which was significantly elevated in allogeneic T cells after HCT in mice. Using genetic and pharmacologic approaches, we demonstrated a key role for miR-31 in mediating donor T-cell pathogenicity in cGVHD. Recipients of miR-31-deficient T cells displayed improved cutaneous and pulmonary cGVHD. Deficiency of miR-31 reduced T-cell expansion and T helper 17 (Th17) cell differentiation but increased generation and function of regulatory T cells (Tregs). MiR-31 facilitated neuropilin-1 downregulation, Foxp3 loss, and interferon-γ production in alloantigen-induced Tregs. Mechanistically, miR-31 was required for hypoxia-inducible factor 1α (HIF1α) upregulation in allogeneic T cells. Therefore, miR-31-deficient CD4 T cells displayed impaired activation, survival, Th17 cell differentiation, and glycolytic metabolism under hypoxia. Upregulation of factor-inhibiting HIF1, a direct target of miR-31, in miR-31-deficient T cells was essential for attenuating T-cell pathogenicity. However, miR-31-deficient CD8 T cells maintained intact glucose metabolism, cytolytic activity, and graft-versus-leukemia response. Importantly, systemic administration of a specific inhibitor of miR-31 effectively reduced donor T-cell expansion, improved Treg generation, and attenuated cGVHD. Taken together, miR-31 is a key driver for T-cell pathogenicity in cGVHD but not for antileukemia activity. MiR-31 is essential in driving cGVHD pathogenesis and represents a novel potential therapeutic target for controlling cGVHD.
引用
- Wu Y, Mealer C, Schutt S, et al. MicroRNA-31 regulates T-cell metabolism via HIF1α and promotes chronic GVHD pathogenesis in mice. Blood Adv. 2022. PMID: 35073581. doi:10.1182/bloodadvances.2021005103
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。